. Author manuscript; available in PMC: 2011 Nov 25.

Published in final edited form as: Oncol Lett. 2011 Nov-Dec;2(6):1131–1137. doi: 10.3892/ol.2011.375

Table I.

List of the antibodies used in the study.

Antibody	Manufacturer
ER-α (clone 6F11), PR (clone 16), Her-2/neu (Clone CB11), cyclin D1	Ventana Medical Systems
EGFR, MAPK1/2 (ERK1/2), pERK1/2 (Thr202/Tyr204)	Cell Signaling Technology
p16 (mouse monoclonal IgG1κ)	Cell Marque
Cyclin D1 (clone SP4 rabbit IgG), GCDFP-15 (clone 23A3 mouse IgG2Aκ), ER-α (Cat no. RB-9016-P)	Neomarkers
EGFR (PharmDX diagnostic kit), Topoisomerase-IIα (Clone Ki-S1), Cytokeratin 5/6 (D5/16B4), p63 (clone 4A4)	DakoCytomation
Rb (IF8): sc-102, pRb(Ser795), p16 (N-20: sc-467),p53 (DO-1): sc-126, Actin [(I-19): sc-1616],AR (clone AR441: sc-7305), pEGFR (Tyr845), Her-2 (Neu (CB11): sc-52349), p-Neu (Tyr 1248)-R: sc-12352-R	Santa Cruz Biotechnology